GLP-1s in a More Mode: More Indications, More Access | Predictions for 2025
Luke Twelves, M.D., vice president of Medical for Lindus Health, shared his prediction for the year.
The GLP-1 [glucagon-like peptide 1] agents are poised to become viable options for treating indications beyond type 2 diabetes and obesity. Recent breakthroughs in research for sleep apnea, polycystic ovarian syndrome, Parkinson’s disease and more have demonstrated their potential.
Twelves
In the coming year, patients will have greater access to these medications than ever before. We’ll see more and more providers integrating GLP-1s into their patients’ treatment plans, indications across various therapeutic areas, and, subsequently, more payers offering coverage for them.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Blue Shield Teams Up With Zocdoc to Make Scheduling Doctor Visits Easier
June 11th 2025The booking feature is now live for all Blue Shield employer-sponsored plans, Individual and Family Plans and Medicare members. The tool provides access to more than 1 million bookable appointment hours across a 90-day window.
Read More
